Dr. Declan Doogan, Interim Chief Executive Officer, is scheduled to present at the Jefferies 2010 Global Life Sciences Conference on Tuesday, June 8, 2010 at 2:30 pm. This conference will be held at the Grand Hyatt in New York City. A live audio webcast of the presentation will be available at www.wsw.com/webcast/jeff46/amrn/.
John Thero, Chief Financial Officer, is scheduled to present at the 9th Annual Needham Healthcare Conference on Wednesday, June 9, 2010 at 4:40 pm. This conference will be held at the New York Palace Hotel in New York City. A live audio webcast of the presentation will be available at www.wsw.com/webcast/needham38/amrn/.
About Amarin
Amarin is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), has commenced enrollment of patients in two pivotal Phase 3 clinical trials for the treatment of patients with very high triglyceride levels and for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials were designed under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.
Contacts: | |
Investor Contact Information: | |
John F. Thero | |
Chief Financial Officer | |
In US: +1 (860) 572 4979 | |
Gitanjali Ogawa | |
The Trout Group | |
In U.S. +1 (646) 378-2949 | |
International Media Contact Information: | |
Mark Swallow or David Dible | |
Citigate Dewe Rogerson | |
In UK: +44 (0)207 638 9571 | |
SOURCE Amarin Corporation plc
